Clinical Scorecard: Case Study: Early Treatment of Geographic Atrophy

At a Glance

Key Highlights

• Early identification and treatment of GA before foveal involvement is critical for preserving vision.
• Complement inhibitor therapy benefits increase with sustained long-term treatment, reducing lesion growth by 20-30% over 36 months.
• Bilateral GA does not require simultaneous treatment; staging by severity and monitoring asymmetric disease guides intervention timing.

Guideline-Based Recommendations

Diagnosis

• Use best-corrected visual acuity (BCVA) assessment and multimodal imaging including color fundus photography and fundus autofluorescence (FAF) to identify GA and assess progression.
• Monitor for hyperautofluorescent borders indicating active progression and evaluate for choroidal neovascularization.

Management

• Initiate FDA-approved intravitreal complement inhibitor therapy in eyes with nonsubfoveal GA showing active progression and preserved foveal islands.
• Defer treatment in eyes with minimal or no atrophy until early central GA emerges.
• Administer injections every other month and maintain long-term treatment commitment.

Monitoring & Follow-up

• Regular imaging follow-up with FAF and OCT to track lesion enlargement and foveal architecture stability.
• Monitor visual acuity to assess treatment efficacy and disease progression.

Risks

• No adverse events observed in this case over more than 2 years of treatment.
• Prior vitrectomy does not appear to diminish treatment response.

Patient & Prescribing Data

Elderly patients with asymmetric bilateral GA, preserved central vision, and active lesion progression

Early treatment in the eye with active nonsubfoveal GA and delayed treatment in the fellow eye upon progression preserves vision and maintains stable visual acuity over years.

Clinical Best Practices

• Identify patients early with nonsubfoveal GA and preserved foveal islands to optimize treatment window.
• Use multimodal imaging to guide timing of intervention, especially in asymmetric disease.
• Encourage patient commitment to long-term intravitreal complement inhibitor therapy for maximal benefit.
• Individualize treatment initiation based on lesion severity and progression rather than simultaneous bilateral treatment.

References

• Complement inhibition reduces GA lesion growth by 20-30% over 36 months
• Clinical trial data supporting sustained complement inhibitor treatment